DOA
SYRS

D'Orazio & Associates’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

D'Orazio & Associates’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10
Closed -$1K – 300
2018
Q1 		$1K Hold
10
– – ﹤0.01% 282
2017
Q4 		$1K Buy
+10
New +$1.34K ﹤0.01% 318

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D'Orazio & Associates's SYRS Position: Q2 2018 in Review

D'Orazio & Associates sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2018, closing a stake of 10 shares — an estimated $1K sold.

D'Orazio & Associates first reported a position in SYRS in Q4 2017 and held it in 2 quarters. The position peaked at $1K in Q1 2018. 76 funds tracked by Wall St. Rank hold SYRS as of Q2 2018.

  • D'Orazio & Associates reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • D'Orazio & Associates sold 10 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $1K.
  • D'Orazio & Associates first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • D'Orazio & Associates's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1K in Q1 2018.
  • 76 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on D'Orazio & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.